Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 1 de 1
Filtrer
Plus de filtres








Gamme d'année
1.
J. venom. anim. toxins incl. trop. dis ; J. venom. anim. toxins incl. trop. dis;14(2): 203-223, 2008.
Article de Anglais | LILACS, SES-SP, SESSP-ILSLPROD, SES-SP, SESSP-ILSLACERVO, SES-SP | ID: lil-484561

RÉSUMÉ

Multidrug-resistant tuberculosis (MDR-TB) is an increasing global problem. The extent and burden of MDR-TB varies significantly from country to country and region to region. Globally, about three per cent of all newly diagnosed patients have MDR-TB and the proportion is higher in patients who had previously received anti-tuberculosis (anti-TB) treatment reflecting the failure of programs designed to ensure complete cure of patients with tuberculosis. The management of MDR-TB is a challenge that should be undertaken by experienced clinicians at centers equipped with reliable laboratory services and implementation of DOTS-Plus strategy.


Sujet(s)
Humains , Gènes MDR , Mycobacterium tuberculosis/génétique , Mycobacterium tuberculosis/virologie , Tuberculose multirésistante/épidémiologie , Tuberculose/épidémiologie
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE